COME FUNZIONANO I VACCINI ANTI COVID-19: UNA GRANDE ARTICOLO DA NATURE
How protein-based COVID vaccines could change the pandemic Jabs from Novavax and other biotech firms are coming. Scientists say they…
Approfondisci...
OCCHIO AL MOLNUPIRAVIR PER OS COME ANTI COVID-19. QUALCHE RIFLESSIONE IN ATTESA DELLA APPROVAZIONE DA MEDICAL NEWS TODAY
COVID19 - EVIDENCE, GASTROENTEROLOGIA, GLOBAL HEALTH, MEDICI DI FAMIGLIA, MEDICINA INTERNABy Redazione
Molnupiravir vs. COVID-19: Will the drug live up to the hype? Katharine Lang In the search for effective COVID-19 treatments,…
TRE GRAVI ERRORI O MITI SUL COVID -19. UN DOC “FREE” DAL REAL CENTRE DOPO UN ANNO DI EPIDEMIA
REAL Centre. One year on Three myths about COVID-19 that the data proved wrong Data analysis (PDF version) • 23…
MORTALITA’ DA COVID-19 vs INFLUENZA: 206 vs 1.8 per 100 000 da BMJ ( GRAN BRETAGNA ED USA).
Covid and flu: what do the numbers tell us about morbidity and deaths? Much confusion has been seen in the…
COME DIAVOLO SPIEGARE QUANTO E’ BASSA LA PROBABILITA’ DI COMPLICAZIONI DA VACCINO ANTI COVID-19 ? IL CASO DELLA TROMBOSI POST-VACCINO AL CONFRONTO CON DECESSO DA ANESTESIA, MORTALITA’ SUL LAVORO O DA INCIDENTE STRADALE
Understanding one in 100,000 What does this tiny probability look like? Anthony B. Masters The EMA stated there was a plausible link…
ANCORA SULLA IVERMECTINA: RICERCA FRAUDOLENTA? PARTE 4/6
Is Ivermectin For Covid-19 Based On Fraudulent Research? Part 4 The story of ivermectin for Covid-19 continues to get even…
DAL “WASHINGTON POST” : 1 AMERICANO SU 500 E’ DECEDUTO PER COVID-19
The pandemic marks another grim milestone: 1 in 500 Americans have died of covid-19 By Dan Keatin , Akilah Johnson and…
COVID-19: ANCORA UNO STUDIO ” NON PEER-REVIEWED” RITIRATO DOPO 150.000 VISIONI. IL CASO IVERMECTIN SU “NATURE”
Flawed ivermectin preprint highlights challenges of COVID drug studies The study’s withdrawal from a preprint platform deals a blow to…
COVID-19: IVERMECTINA SOTTO STUDIO CON QUALCHE POLEMICA. UNA NOTA DALLA BIBLIOTECA DELLA ASSOCIAZIONE LIBERATI
Covid-19: ivermectina alla prova Pubblicato martedì 21 Settembre 2021 Sulla base delle prove attuali, non c’è sufficiente certezza sull’efficacia e…
BUDESONIDE SPRAY PER COVID-19: RIDUZIONE DEL 2% DI RICOVERO O DECESSO NEL PAZIENTE A DOMICILIO A RISCHIO DI COMPLICANZE
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised,…
LA GRANDE STORIA DEI VACCINI A mRNA DA NATURE
COVID19 - EVIDENCE, GASTROENTEROLOGIA, INTERNATIONAL SNAPSHOTS, MEDICI DI FAMIGLIA, MEDICINA INTERNABy Redazione
The tangled history of mRNA vaccines Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic…
FDA AUTORIZZA IN EMERGENZA L’USO DI TOCILIZUMAB NEI PAZIENTI OSPEDALIZZATI PER COVID-19
Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19 Today, the U.S. Food and Drug Administration issued an emergency use…
GLI ANTAGONISTI DELLA IL-6 RIDUCONO LA MORTALITA’ DA COVID-19 NEGLI OSPEDALIZZATI: UNA META-ANALISI DAL GRUPPO WHO
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. A Meta-analysis The WHO Rapid Evidence Appraisal…
POVERA EBM: I DUBBI SULL’ULTIMO TRIAL ANTI COVID-19. RIDUZIONE DELLA MORTALITA’ DEL 77% ? DA “SCIENCE”
‘Too good to be true’: Doubts swirl around trial that saw 77% reduction in COVID-19 mortality Robert F. Service Science’s…
SARA’ LA GRAN BRETAGNA IL PRIMO PAESE AD ARRENDERSI AL COVID? UN’AMARA RIFLESSIONE SU “MEDIUM”
How Britain Became the First Country in the World to Surrender to Covid This is What it Means to Be…
REAL WORLD EVIDENCE : EVENTI TROMBOTICI DOPO VACCINO ASTRA NELLA POPOLAZIONE DELLA NORVEGIA E DANIMARCA
Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study…
I PROBIOTICI DI PROSSIMA GENERAZIONE: UNA MAGNIFICA REVIEW ! (ANCHE CONTRO IL COVID-19?)
Next-Generation Probiotics and Their Metabolites in COVID-19 Thomas Gautier et al. Abstract: Since December 2019, a global pandemic has been…
TOFACITINIB FUNZIONA: RIDUZIONE DECESSI DA POLMONITE PER COVID-19 DEL 37 %
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia Patrícia O. Guimarães et al. BACKGROUND The efficacy and safety of tofacitinib, a…
I PRIMI 100 GIORNI DEL COVID-19: LA EBM RISCHIA LA “DEBACLE”
Recruitment and Results Reporting of COVID-19 Randomized Clinical Trials Registered in the First 100 Days of the Pandemic Perrine Janiaud,…
LE PUBBLICAZIONI “PRE-PRINT” DISTURBANO LA EBM: UN COMMENTO SULLE REVIEWS IN TEMPI DI COVID-19
Using Preprints in Evidence Synthesis: Commentary on experience during the COVID-19 pandemic Barbara Clyne et al. Introduction SARS-CoV-2, the virus…
L’INTESTINO COME “RESERVOIR” PER I VIRUS : LA LEZIONE DEL COVID-19
COVID19 - EVIDENCE, GASTROENTEROLOGIA, GLOBAL HEALTH, MEDICINA INTERNA, MICROBIOTA, REAL WORLD EVIDENCEBy Redazione
Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19 Markus F Neurath et al. Background: viruses in the…
IDROSSICLOROCHINA AUMENTA LA MORTALITA’ PER COVID-19: UNA META-ANALISI COLLABORATIVA DA “NATURE COMMUNICATIONS”
COVID19 - EVIDENCE, EPATOLOGIA, GASTROENTEROLOGIA, INTERNATIONAL SNAPSHOTS, MEDICI DI FAMIGLIA, MEDICINA INTERNA, Senza categoriaBy Redazione
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials Cathrine Axfors, Andreas M.…
BAYES E VACCINO PFIZER-BIONTECH: UNA ATTENTA ANALISI SULLA EFFICACIA. DO YOU BAYES ? PARTE SECONDA
Bayesian Statistics of Efficacy of Pfizer-BioNTech COVID-19 Vaccine — part II Reproducing original results Bartek Skorulski Part II (this post)…
